A Survey of Survival Outcomes for Targeted Cancer Drugs Approved by the US Food and Drug Administration

Cancer treatment and survivorship statistics, 2019

(2019) Kimberly D. Miller et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Molecular targeted therapy: treating cancer with specificity

(2018) Yeuan Ting Lee et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology

(2018) Alyson Haslam et al.   EUROPEAN JOURNAL OF CANCER

Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration

(2017) Huseyin Naci et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Combination immunotherapy: a road map

(2017) Patrick A. Ott et al.   Journal for ImmunoTherapy of Cancer

Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

(2015) Padmanee Sharma et al.   CELL

Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non–Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses

(2015) Gideon M. Blumenthal et al.   JOURNAL OF CLINICAL ONCOLOGY

Faster Drug Approvals Are Not Always Better and Can Be Worse

(2015) Rita F. Redberg   JAMA Internal Medicine

The Strength of Association Between Surrogate End Points and Survival in Oncology

(2015) Vinay Prasad et al.   JAMA Internal Medicine

Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non–Small-Cell Lung Cancer

(2015) Darius N. Lakdawalla et al.   JAMA Oncology

Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012

(2014) Nicholas S. Downing et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Surrogate Outcomes in Clinical Trials

(2013) Staffan Svensson et al.   JAMA Internal Medicine

Reputation and Precedent in the Bevacizumab Decision

(2011) Daniel Carpenter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Addition of Bevacizumab to Chemotherapy for Treatment of Solid Tumors: Similar Results but Different Conclusions

(2010) Alberto Ocaña et al.   JOURNAL OF CLINICAL ONCOLOGY

Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials

(2009) Qian Shi et al.   International Journal of Clinical Oncology

Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs

(2009) Beata Zahorowska et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Endpoints for Assessing Drug Activity in Clinical Trials

(2008) R. Pazdur   ONCOLOGIST